Rosenstein Justin

Director Rosenstein sold 858,448 shares ($13.0M) in 2 transactions; post-sale holdings drop 80.3% to 210,398 shares

Justin Rosenstein, Asana Director, executed 2 separate sales totaling 858,448 shares for $12,978,252.19 on December 8–9, 2025, reducing his holdings from 1,068,846 shares to 210,398 shares—an 80.3% reduction. At the blended average price of $15.12, the transaction occurred when ASAN traded 3.7% above the current price of $14.58, though the stock remains 47.0% below its 52-week high of $27.52. His prior trades at ASAN show a 2-of-2 pattern of well-timed 90-day outcomes, but this sale post-dates the most recent measurable outcome, so near-term consequences remain unclear. Asana's fundamentals show unprofitability (net income of $-68,433,000.00 in the latest quarter and negative full-year net income), though the company achieved 10.9% annual revenue growth to $201,033,000.00, creating a context of operational losses amid modest growth.

Director Justin Rosenstein sells 458.9K ASAN shares ($6.9M) at $14.98; stock down 46.8% from 52-week high

Justin Rosenstein, a Director, sold 458,878 shares (29.8% of his pre-transaction holdings) at $14.98 on 2025-10-21, reducing his position from 1,541,425 to 1,082,547 shares. The sale occurred as Asana trades at $14.64, down 46.8% from its 52-week high of $27.52, and follows a pattern of repeated selling: Rosenstein executed two additional ASAN sales on 2025-10-09 and 2025-10-08 (outcome not yet measurable), plus three sales in late July that yielded negative 30-day and 90-day returns. His cross-ticker track record shows a 94.12% well-timed rate on 20 prior sells across all tickers, with average 90-day returns of -9.6%, indicating a historical pattern of selling before subsequent declines. At the same-ticker level, his two measurable ASAN sales (2025-07-25 and 2025-07-24) both posted negative 90-day returns, extending a pattern of well-timed exit points. The company remains unprofitable (net income of $-48.4M on $196.9M quarterly revenue) despite 10.9% annual revenue growth, creating fundamental headwinds that contextual timing patterns may reflect.

Director Justin Rosenstein sold 1,654,473 shares (51.5% of holdings) at $15.08–$15.23 for $25.1M; stock now at $13.63, -50.5% from 52-week high.

Director Justin Rosenstein executed two separate sales totaling 1,654,473 shares for $25,135,678.17, reducing his holdings from 3,210,398 shares to 1,555,925 shares (a 51.5% reduction). The sales occurred at $15.08 on 2025-10-08 and $15.23 on 2025-10-09, with a blended average price of $15.19. The current price of $13.63 represents a decline of approximately $1.56 from the transaction prices, placing the stock 50.5% below its 52-week high of $27.52. Rosenstein's prior sales at Asana all showed negative 30-day returns (ranging from -3.4% to -8.9%), and his cross-ticker track record shows 20 prior sells with a 90-day well-timed rate of 92.31%, suggesting a pattern of selling into weakness. The company remains unprofitable (net income of -$48.4M in the latest quarter) despite 10.9% annual revenue growth, which may be contextually relevant to the timing of this substantial position reduction.

Director Rosenstein sold 517,635 shares of ASAN at $15.04 on 2025-07-28 (total $7.8M); following 4 consecutive daily sales. Stock now -44.2% from 52-week high.

Director Justin Rosenstein executed a sale of 517,635 shares at $15.04, reducing his holdings by 13.9% to 3,210,398 shares. This transaction continues a pattern of rapid liquidation, with five consecutive daily sales from 2025-07-21 through 2025-07-28. The timing is notable: the stock has fallen 4.4% over the past 90 days and stands 44.2% below its 52-week high of $27.52, yet Rosenstein's cross-ticker track record shows a 92.86% well-timed sell rate. The company remains unprofitable (net income of $-40,018,000 in the latest quarter) despite modest revenue growth of 10.9%, which provides fundamental context for insider liquidity decisions. The pattern of systematic daily selling—rather than a single opportunistic trade—combined with the stock's significant decline from peak may signal confidence in timing, but investors should note this is measured against the director's historical performance across all holdings, not specifically within ASAN.

Director Rosenstein sold 339,830 shares ($5.1M) at $15.00 avg; stock now $15.03, -45.4% from 52-week high.

Justin Rosenstein, a Director at Asana, executed 2 separate sales on 2025-07-24 and 2025-07-25, totaling 339,830 shares for $5,096,356.61 at a blended average price of $15.00. This represents an 8.4% reduction of his holdings, leaving him with 3,728,033 shares post-transaction. The timing is notable: ASAN trades at $15.03 currently, -45.4% from its 52-week high of $27.52, having recovered +13.2% over the prior 30 days. Rosenstein's cross-ticker track record shows a 90-day well-timed rate of 93.33%, indicating his prior sells have historically preceded declines; however, he has 5 other recent sells at ASAN (spanning 2025-07-18 through 2025-07-28) with no measurable 90-day outcomes yet. The company remains unprofitable with a net loss of $40,018,000 on revenue of $187,267,000, though annual revenue growth stands at 10.9%.

Director Rosenstein sells 1,695,804 shares (1.70M) at $15.04–$15.08 for $25.5M; retains 4.07M shares post-sale

Justin Rosenstein, Director at Asana, executed 2 separate sales totaling 1,695,804 shares for $25,533,360.94 at blended average price $15.06 on July 22–23, 2025. This represents a -29.4% reduction from his pre-transaction holdings of 5,763,667 shares, leaving him with 4,067,863 shares. The sales occurred as the stock trades at $14.94 (current), down -45.7% from its 52-week high of $27.52, and the company remains unprofitable with a net income of $-40,018,000.00 against quarterly revenue of $187,267,000.00. His prior trades at ASAN show mixed timing outcomes: the March 2025 sales generated +20.6% 30-day return and +9.7% 90-day return on one, and +11.4% 30-day and -0.9% 90-day on another, with 1 of 2 prior sells well-timed at the 90-day mark. The cross-ticker track record shows a 93.75% well-timed rate across 19 prior sells (average 90d return -16.0%), but this current filing's measurable outcomes are not yet determinable. The sale volume and dollar amount are material relative to his post-transaction stake.

Director Rosenstein sold 421,731 shares of ASAN (6.8% of holdings) for $6,324,792.37 across 2 transactions at blended avg $15.00

Rosenstein filed 2 separate sales totaling 421,731 shares for $6,324,792.37, reducing his position from 6.19M to 5.76M shares. The transactions executed at $14.99–$15.01, near current price of $15.03, during a period of 30-day momentum (+14.3%) but substantial recovery from the 52-week low of $11.17. His prior trades at ASAN show mixed outcomes: 3 of 4 prior measurable sales were well-timed at the 90-day mark, suggesting some pattern of selling before declines, though his cross-ticker track record shows an average 90-day return of -16.0% after sales with a 93.75% well-timed rate. The company remains unprofitable (net income $-40.0M) despite 10.9% annual revenue growth, adding context to the sale timing relative to fundamentals. This represents a substantial reduction in director holdings but at prices neither materially elevated nor depressed relative to recent history.

Director Justin Rosenstein sold 100,000 ASAN shares ($1.4M) at $12.89–$13.96 as stock tumbles -39.6% in 30 days.

Director Justin Rosenstein executed 2 separate sales totaling 100,000 shares for $1,369,250.00 across March 13–14, with a blended average price of $13.69. The timing is notable: Asana's stock has declined -39.6% over the past 30 days and is trading -48.9% below its 52-week high of $27.52, at a current price of $14.06. Rosenstein retains 847,309 shares post-transaction, representing a -10.6% reduction in holdings. The company remains unprofitable (latest quarter net income: $-57,326,000.00) despite moderate revenue growth of +19.2% year-over-year, creating structural earnings headwinds. His cross-ticker track record shows 14 prior sells with an average 30-day return of -16.1%, though same-ticker trading outcomes at ASAN remain unmeasurable due to recent timing.

Director Rosenstein sells 150,000 ASAN shares at $18.97 avg (5th consecutive sale in 2 weeks)

Rosenstein sold 150,000 shares (two separate sales on 2025-03-03 totaling 150.0K shares) at a blended average price of $18.97, reducing his holdings from 1.10M to 947.3K shares (-13.7% reduction). This sale continues an aggressive recent pattern: five prior sales at ASAN occurred between 2025-02-12 and 2025-02-24, all within two weeks preceding this filing. The current stock price of $18.96 is -31.1% from the 52-week high of $27.52, creating a contextual backdrop of stock weakness. While the company reported annual revenue growth of +19.2%, it remains unprofitable with net income of -$57.3M on quarterly revenue of $183.9M. The concentrated timing of five sequential sales within days suggests deliberate liquidation rather than a single discretionary transaction.

Director Rosenstein sells 150,000 shares at blended $19.76; 5th sale in 10 days; retains 1.10M shares post-transaction.

Rosenstein executed 2 separate sales totaling 150,000 shares for $2,963,661.75 on 2025-02-24, at a blended average price of $19.76. This transaction continues a concentrated selling pattern: Rosenstein has sold 5 times at ASAN in the past 10 days (2025-02-05, 2025-02-12, 2025-02-19, 2025-02-24), with timing outcomes not yet measurable on any prior ASAN trades. Post-transaction holdings of 1,097,309 shares represent a -12.0% reduction from pre-transaction holdings. The sales occur as ASAN trades -29.2% from its 52-week high of $27.52, while the company reported a net loss of $-57,326,000.00 on revenue of $183,882,000.00 in its latest quarter. The frequency and magnitude of sales warrant investor attention to whether this pattern reflects director positioning in the context of the company's unprofitable status.